GlassScriptPhysician profile
Lane M Cook
NPI 1174509590
$52,524.04
in general payments reported to CMS, 2019-2025
29 companies · $1,598 in 2025
The $1,598 reported for 2025 was more than what 87% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $1,639 · 2021: $14K · 2022: $8,724 · 2023: $2,263 · 2024: $1,832 · 2025: $1,598.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,443 · Education: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,442.90 |
| Education | $250.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $37,150.99 | 2019-2025 | Lybalvi, Aristada, Vivitrol |
| Takeda Pharmaceuticals U.S.A., INC. | $6,188.53 | 2019-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $2,271.95 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,193.27 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $999.84 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $963.62 | 2019-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $633.95 | 2023-2025 | Auvelity, Sunosi |
| Vanda Pharmaceuticals INC. | $452.96 | 2020-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $437.42 | 2019-2025 | Spravato |
| Abbvie INC. | $387.79 | 2021-2025 | Vraylar |
| Corium, LLC | $347.31 | 2022-2024 | Azstarys |
| Sunovion Pharmaceuticals INC. | $265.76 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $252.69 | 2021-2024 | |
| Lundbeck LLC | $163.20 | 2019-2025 | Rexulti |
| Tris Pharma INC | $136.27 | 2023-2024 | Dyanavel Xr |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $127.89 | 2022-2023 | Wakix |
| Eisai INC. | $82.25 | 2020-2022 | |
| Almatica Pharma LLC | $79.23 | 2023-2024 | Loreev Xr |
| Ironshore Pharmaceuticals INC. | $78.97 | 2019-2024 | |
| Supernus Pharmaceuticals, INC. | $67.72 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $61.41 | 2024 | Cobenfy |
| Bausch Health US, LLC | $42.00 | 2022-2023 | Aplenzin |
| Shire North American Group INC | $31.30 | 2019 | |
| Allergan, INC. | $27.05 | 2019-2020 | |
| Neos Therapeutics, LP | $21.12 | 2025 | Exxua |
| Idorsia Pharmaceuticals US INC | $16.40 | 2023 | Quviviq |
| Mdd US Operations, LLC | $15.84 | 2019 | |
| Uswm, LLC | $15.55 | 2021 | |
| Merck Sharp & Dohme LLC | $11.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lane Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.